| · Журналы
· Книги
· О проекте
·Электронные версии книг издательства “Атмосфера” поступили в продажу
Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания.
Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru
ИНТЕРНЕТ-МАГАЗИН
|
|
 | |
Атмосфера. Новости кардиологии
2023 / N 3
Что сказать пациенту о безопасности статинов? Новые ответы на старые вопросы
Ю.Г. Шварц
References
1. Карпов Ю.А. Новый вектор снижения сердечнососудистого риска – интенсивная гиполипидемическая терапия. Атмосфера. Новости кардиологии 2023;1:310.
2. Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statins impair cognition? A systematic review and metaanalysis of randomized controlled trials. Journal of General Internal Medicine 2015 Mar;30(3):34858.
3. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The Lancet 2002 Nov;360(9386):162330.
4. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) – can Creactive protein be used to target statin therapy in primary prevention? The American Journal of Cardiology 2006 Jan;97(2A):33A41A.
5. Keen HI, Krishnarajah J, Bates TR, Watts GF. Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? Expert Opinion on Drug Safety 2014 Sep;13(9):122739.
6. Backes JM, Ruisinger JF, Gibson CA, Moriarty PM. Statinassociated muscle symptoms – managing the highly intolerant. Journal of Clinical Lipidology 2017 JanFeb;11(1):2433.
7. SelvaO’Callaghan A, AlvaradoCardenas M, PinalFernández I, TralleroAraguás E, Milisenda JC, Martínez MÁ, Marín A, LabradorHorrillo M, Juárez C, GrauJunyent JM. Statininduced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Review of Clinical Immunology 2018 Mar;14(3):21524.
8. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMGCoA reductase inhibitor. Cardiovascular Drug Reviews 2003 Fall;21(3):199215.
9. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. International Journal of Clinical Practice 2005 Feb;59(2):23952.
10. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clinical Biochemistry 2007 Jun;40(910):57584.
11. Fong CW. Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3hydroxy3methylglutarylCoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. European Journal of Medicinal Chemistry 2014 Oct;85:66174.
12. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & Clinical Pharmacology 2005;19:11725.
13. Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care 2013 Aug;36(Suppl 2):S32530.
14. Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and newonset diabetes: a review of proposed mechanisms. Metabolism 2014 Jun;63(6):73545.
15. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J, Tashakkor AY. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update (2016). The Canadian Journal of Cardiology 2016 Jul;32(7 Suppl):S3565.
16. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal 2018 Jul;39(27):252639.
17. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Current Medical Research and Opinion 2009 Nov;25(11):275564.
18. Niemi M. Transporter pharmacogenetics and statin toxicity. Clinical Pharmacology & Therapeutics 2010 Jan;87(1):1303.
19. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ. Inhibitors of 3hydroxy3methylglutarylCoA reductase reduce receptormediated endocytosis in opossum kidney cells. Journal of the American Society of Nephrology 2004 Sep;15(9):225865.
20. Athyros VG, Boutari C, Stavropoulos K, Anagnostis P, Imprialos KP, Doumas M, Karagiannis A. Statins: an underappreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Current Vascular Pharmacology 2018;16(3):24653.
21. Björnsson ES. Hepatotoxicity of statins and other lipidlowering agents. Liver International 2017 Feb;37(2):1738.
22. Xingfen Z, Dandi L, Rongrong F, Feng W, Digcheng Z, Xueqiang M. Association between statins types with incidence of liver cancer: an updated metaanalysis. Current Medicinal Chemistry 2023;31(6):76275.
23. Nunes M, Duarte D, Vale N, Ricardo S. Pitavastatin and ivermectin enhance the efficacy of paclitaxel in chemoresistant highgrade serous carcinoma. Cancers 2022 Sep;14(18):4357.
24. Su CH, Islam MM, Jia G, Wu CC. Statins and the risk of gastric cancer: a systematic review and metaanalysis. Journal of Clinical Medicine 2022 Dec;11(23):7180.
25. Islam MM, Poly TN, Walther BA, Yang HC, Li YC. Statin use and the risk of hepatocellular carcinoma: a metaanalysis of observational studies. Cancers 2020 Mar;12(3):671.
26. Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of pancreatic cancer: a metaanalysis. Digestive and Liver Disease 2019 Jan;51(1):2837.
27. Kim DS, Kim HJ, Ahn HS. Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean National Health Insurance Claims database. Journal of Cancer Research and Clinical Oncology 2022 Oct;148(10):285565.
28. Cho MH, Yoo TG, Jeong SM, Shin DW. Association of aspirin, metformin, and statin use with gastric cancer incidence and mortality: a nationwide cohort study. Cancer Prevention Research (Philadelphia, Pa.) 2021 Jan;14(1):95104.
29. You HS, You N, Lee JW, Lim HJ, Kim J, Kang HT. Inverse association between statin use and stomach cancer incidence in individuals with hypercholesterolemia, from the 2002–2015 NHISHEALS data. International Journal of Environmental Research and Public Health 2020 Feb;17(3):1054.
30. Swanson KM, Hohl RJ. Anticancer therapy: targeting the mevalonate pathway. Current Cancer Drug Targets 2006 Feb;6(1):1537.
31. Dimmeler S, Aicher A, Vasa M, MildnerRihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, Zeiher AM. HMGCoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3kinase/Akt pathway. The Journal of Clinical Investigation 2001 Aug;108(3):3917.
32. Pereira M, Matuszewska K, Glogova A, Petrik J. Mutant p53, the mevalonate pathway and the tumor microenvironment regulate tumor response to statin therapy. Cancers 2022;14(14):3500.
33. Göbel A, Rauner M, Hofbauer LC, Rachner TD. Cholesterol and beyond – the role of the mevalonate pathway in cancer biology. Biochimica et Biophysica Acta. Reviews on Cancer 2020 Apr;1873(2):188351.
34. Likus W, Siemianowicz K, Bieńk K, Pakuła M, Pathak H, Dutta C, Wang Q, Shojaei S, Assaraf YG, Ghavami S, CieślarPobuda A, Łos MJ. Could drugs inhibiting the mevalonate pathway also target cancer stem cells? Drug Resistance Updates 2016 Mar;25:1325.
35. Iuliano L, Crick PJ, Zerbinati C, Tritapepe L, AbdelKhalik J, Poirot M, Wang Y, Griffiths WJ. Cholesterol metabolites exported from human brain. Steroids 2015 Jul;99(Pt B):18993.
36. Dias HK, Brown CL, Polidori MC, Lip GY, Griffiths HR. LDLlipids from patients with hypercholesterolaemia and Alzheimer’s disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention. Clinical Science (London, England: 1979) 2015 Dec;129(12):1195206.
37. Abbott NJ, Friedman A. Overview and introduction: the bloodbrain barrier in health and disease. Epilepsia 2012 Nov;53(Suppl 6):16.
38. U.S. Food and Drug Administration. FDA Consumer Health Information: FDA expands advice on statin risks, 2012. Available from: https://www.fda.gov/drugs/informationdrugclass/statins Accessed 2023 Nov 09.
39. van Vliet P, van de Water W, de Craen AJM, Westendorp RGJ. The influence of age on the association between cholesterol and cognitive function. Experimental Gerontology 2009 JanFeb;44(12):11222.
40. Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A largescale, longterm prospective postmarketing surveillance of pitavastatin (LIVALO Tablet) – LIVALO Effectiveness and Safety (LIVES) study. Japanese Pharmacology and Therapeutics 2008 Jan;36(8):70931.
41. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Journal of Clinical Lipidology 2009 Jun;4(9):291302.
42. De Giorgi R, Cowen PJ, Harmer CJ. Statins in depression: a repurposed medical treatment can provide novel insights in mental health. International Review of Psychiatry (Abingdon, England) 2022 NovDec;34(78):699714.
43. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging study. The Journal of Urology 2000 Feb;163(2):4603.
44. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and metaanalysis of randomized controlled trials. BMC Medicine 2013 Feb;11:57.
45. Tamás V, Kempler P. Sexual dysfunction in diabetes. Handbook of Clinical Neurology 2014;126:22332.
46. Hsieh CJ, Huang B. Rosuvastatin decreases testosterone level but not sexual function in men with type 2 diabetes. Diabetes Research and Clinical Practice 2016 Oct;120:818.
47. Cai X, Tian Y, Wu T, Cao CX, Bu SY, Wang KJ. The role of statins in erectile dysfunction: a systematic review and metaanalysis. Asian Journal of Andrology 2014 MayJun;16(3):4616.
48. Scicali R, Russo GI, Di Mauro M, Manuele F, Di Marco G, Di Pino A, Ferrara V, Rabuazzo AM, Piro S, Morgia G, Purrello F. Analysis of arterial stiffness and sexual function after adding on PCSK9 inhibitor treatment in male patients with familial hypercholesterolemia: a single lipid center realworld experience. Journal of Clinical Medicine 2020 Nov;9(11):3597.
49. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, LloydJones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014 Jul;63(25 Pt B):2889934.
50. American Diabetes Association. 9. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes – 2018. Diabetes Care 2018;41(Suppl 1):S86104.
51. Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matchedcohort study. JAMA Internal Medicine 2021 Dec;181(12):156274.
52. Ishak AM, Matheu C, Ildiko L, Song Z, Ethan AH, Carlos AA. Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: a retrospective cohort study. PLoS One 2022 Jul;17(7):e0269982.
53. Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, You SC, Park RW, Park YM, Kim KJ, Rhee SY, Park M, Jin ES, Kim SE. Impact of pitavastatin on newonset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 realworld databases. Cardiovascular Diabetology 2022 May;21(1):82.
54. Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network metaanalysis. Pharmacoepidemiology and Drug Safety 2016 Oct;25(10):113149.
55. Yoon D, Sheen SS, Lee S, Choi YJ, Park RW, Lim HS. Statins and risk for newonset diabetes mellitus: a realworld cohort study using a clinical research database. Medicine 2016 Nov;95(46):e5429.
56. Choi JY, Choi CU, Hwang SY, Choi BG, Jang WY, Kim DY, Kim W, Park EJ, Lee S, Na JO, Kim JW, Kim EJ, Rha SW, Park CG, Seo HS, Chae SC, Kim YJ, Cho MC, Kim CJ, Kim HS, Jeong MH; KAMIRNIH Investigators. Effect of pitavastatin compared with atorvastatin and rosuvastatin on newonset diabetes mellitus in patients with acute myocardial infarction. The American Journal of Cardiology 2018 Sep;122(6):9228.
57. Cui JY, Zhou RR, Han S, Wang TS, Wang LQ, Xie XH. Statin therapy on glycemic control in type 2 diabetic patients: a network metaanalysis. Journal of Clinical Pharmacy and Therapeutics 2018 Aug;43(4):55670.
58. Odawara M, Yamazaki T, Kishimoto J, Ito C, Noda M, Terauchi Y, Shiba T, Katazato H, Maemura K, Tobe K, Iwamoto Y, Akanuma Y, Kadovaki T. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance. Diabetologia 2013 Sep;56:59.
59. Yamazaki T, Kishimoto J, Ito C, Noda M, Odawara M, Terauchi Y, Shiba T, Kitazato H, Iwamoto Y, Akanuma Y, Kadowaki T. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the JPREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetology International 2011;2:13440.
60. Барбараш О.Л., Дупляков Д.В., Затейщиков Д.А., Панченко Е.П., Шахнович Р.М., Явелов И.С., Яковлев А.Н., Абугов С.А., Алекян Б.Г., Архипов М.В., Васильева Е.Ю., Галявич А.С., Ганюков В.И., Гиляревский С.Р., Голубев Е.П., Голухова Е.З., Грацианский Н.А., Карпов Ю.А., Космачева Е.Д., Лопатин Ю.М., Марков В.А., Никулина Н.Н., Певзнер Д.В., Погосова Н.В., Протопопов А.В., Скрыпник Д.В., Терещенко С.Н., Устюгов С.А., Хрипун А.В., Шалаев С.В., Шпектор А.В., Якушин С.С. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал 2021;26(4):4449.
61. Hong YJ, Jeong MH, Bae JH, Oh SK, Rha SW, Hur SH, Lee SY, Kim SW, Cha KS, Chae IH, Ahn TH, Kim KS. Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. The Korean Journal of Internal Medicine 2017 Jul;32(4):65667.
62. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2016 Oct;37(39):29993058.
63. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020 Jan;41(1):11188.
|
[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ] |
|
|
